Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy

Oncotarget. 2020 Jun 23;11(25):2462-2463. doi: 10.18632/oncotarget.27403.

Caroline M Robb¹, Smit Kour¹, Jacob I Contreras¹, Ekta Agarwal¹, Carter J Barger¹, Sandeep Rana¹, Yogesh Sonawane¹, Beth K Neilsen¹, Margaret Taylor¹, Smitha Kizhake¹, Rhishikesh N Thakare², Sanjib Chowdhury³, Jing Wang^{1

4}, Jennifer D Black^{1

4}, Michael A Hollingsworth^{1

4}, Michael G Brattain^{1

4

5}, Amarnath Natarajan^{1

2

4}

¹ Eppley Institute for Research in Cancer, University of Nebraska Medical Center, 985950 Nebraska Medical Center, Omaha, Nebraska 68198-5950, USA.
² Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, Nebraska 68198-5950, USA.
³ Section of Gastroenterology, Department of Medicine, Boston University Medical Center, Boston, Massachusetts 02118, USA.
⁴ Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska 68198-5950, USA.
⁵ Deceased.

Abstract

[This corrects the article DOI: 10.18632/oncotarget.23749.].